(R)-(+)-2-phenylpropyl p-toluenesulfonate | 158581-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-(+)-2-phenylpropyl p-toluenesulfonate
• 英文别名: (R)-2-Phenylpropyltosylat；(R)-2-phenyl-1-propyltoluenesulphonate；(R)-2-phenylpropyl 4-methylbenzenesulfonate；toluene-4-sulfonic acid (R)-2-phenyl-propyl ester；toluene-4-sulfonic acid (R)-2-phenylpropyl ester；[(2R)-2-phenylpropyl] 4-methylbenzenesulfonate
• CAS: 158581-57-8
• 化学式: C₁₆H₁₈O₃S
• 分子量: 290.383
• InChiKey: LWODUZBQQRSKOF-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-(+)-2-phenylpropyl p-toluenesulfonate 在 palladium on activated charcoal copper(l) iodide 、 硫酸 、 氢气 、 硝酸 作用下， 以 乙醇 、 水 为溶剂， -30.0~40.0 ℃ 、248.21 kPa 条件下， 反应 3.0h， 生成 (R)-(-)-p-(2-methylhexyl)aniline
  参考文献：
  名称：

  (S)-(-)-乳酸乙酯作为合成手性液晶的方便前体

  摘要：

  摘要 提出了一种合成源自乳酸 (S)-(-)-乙酯的光学活性前体的策略，用于合成手性液晶。

  DOI：

  10.1080/00397919308018611
• 作为产物：
  描述：

  (R)-(+)-2-苯基-1-丙醇 、 对甲苯磺酰氯 在 N,N-二乙基甲胺 作用下， 以 二氯甲烷 为溶剂， 生成 (R)-(+)-2-phenylpropyl p-toluenesulfonate
  参考文献：
  名称：

  Transformation from [Au₂₅(SCH₂CH₂CH₂CH₃)₁₈]⁰ to Au₂₈(SCH₂CH(CH₃)Ph)₂₁ gold nanoclusters: gentle conditions is enough

  摘要：

  在这里，我们报告了在温和条件下通过配体交换反应将[Au₂₅(SR)₁₈]⁰转化为Au₂₈(SR)₂₁的过程。

  DOI：

  10.1039/c9cc08872e

文献信息

• 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
  申请人：Drescher Karla

  公开号：US20080318996A1

  公开（公告）日：2008-12-25

  The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R 6 and wherein Ar may also carry I or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C4-cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2, 3 or 4; R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof.

  本发明涉及式（I）的6-氨基（氮）吲哚化合物，其中Ar是苯或芳香5-或6-成员C-连接的杂环芳基，其中Ar可以携带1个基团R6，Ar还可以携带1或2个基团Rb；X是N或CH；E是CR6R7或NR3；R1是C1-C4烷基、C3-C4环烷基、C3-C4环烷基甲基、C3-C4烯基、氟代C1-C4烷基、氟代C3-C4环烷基、氟代C3-C4环烷基甲基、氟代C3-C4烯基、甲酰基或C1-C3烷基羰基；R1a是H或R1a和R2或R1a和R2a一起是（CH2）n，其中n为1、2、3或4；R2和R2a各自独立地是H、CH3、CH2F、CHF2或CF3；R3是H或C1-C4烷基；以及这些化合物的生理上耐受的酸加成盐。该发明还涉及包含式（I）的至少一种化合物或其药学上可接受的盐的制药组合物，以及一种用于治疗对多巴胺D3受体配体敏感的医学疾病的方法，该方法包括给予至少一种式（I）的化合物或其药学上可接受的盐的有效量。
• Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor
  申请人：Drescher Karla

  公开号：US20080045493A1

  公开（公告）日：2008-02-21

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、C1-C6烷基取代的C3-C6环烷基、C1-C6羟基烷基、氟代C1-C6烷基、C3-C6环烷基、氟代C3-C6环烷基、C3-C6烯基、氟代C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被一个或多个卤素、甲基、甲氧基和CF3等取代基所取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、一个5-或6-成员的杂环芳基基团中选择的循环基团，该杂环芳基基团的环成员包括1、2或3个从N、O和S选择的杂原子和与饱和或不饱和的5-或6-成员碳环或杂环芳基团融合的苯基环，其中所述杂环芳基团包括1、2或3个从N、O和S选择的杂原子和/或1、2或3个从NR8选择的含杂原子基团，其中R8为H、C1-C4烷基、氟代C1-C4烷基、C1-C4烷基羰基或氟代C1-C4烷基羰基，且所述循环基团Ar可以携带1、2或3个取代基Ra，其中变量Ra的含义如权利要求和说明书中所给出；以及其生理耐受的酸加合盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易于用多巴胺D3受体配体治疗的医疗疾病的药物组合物的用途。
• Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor
  申请人：Drescher Karla

  公开号：US20090012074A1

  公开（公告）日：2009-01-08

  The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; Y is O, S, —CH═N—, —CH═CH— or —N═CH—; A is CH 2 , O or S; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1a and R 2a together are (CH 2 ) n with n being 2 or 3; R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及公式I的芳香族化合物，其中Ar是苯基或含有5或6个成员的芳香族C-连接杂环基团，其中Ar可以携带1个基团Ra，也可以携带1或2个基团Rb；X是N或CH；Y是O，S，-CH═N-，-CH═CH-或-N═CH-；A是CH2，O或S；E是CR6R7或NR3；R1是C1-C4烷基，C3-C4环烷基，C3-C4环烷基甲基，C3-C4烯基，氟代C1-C4烷基，氟代C3-C4环烷基，氟代C3-C4环烷基甲基，氟代C3-C4烯基，甲酰基或C1-C3烷基羰基；R1a是H，C2-C4烷基，C3-C4环烷基，C3-C4烯基，氟代C1-C4烷基，氟代C3-C4环烷基，或R1a和R2一起是(CH2)n，其中n为2或3，或R1a和R2a一起是(CH2)n，其中n为2或3；R2和R2a相互独立地是H，CH3，CH2F，CHF2或CF3；R3是H或C1-C4烷基；R6，R7相互独立地选择自H，C1-C2烷基和氟代C1-C2烷基；以及其生理耐受酸盐。本发明还涉及使用公式I的化合物或其药学上可接受的盐制备用于治疗可通过多巴胺D3受体配体治疗的医疗障碍的制药组合物的用途。
• Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
  申请人：Drescher Karla

  公开号：US20090048326A1

  公开（公告）日：2009-02-19

  The present invention relates to a compound of the formula (I) wherein R 1 is H, C 1 -C 6 -alkyl which may be substituted by C 3 -C 6 -cycloalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a ; wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及一种式（I）的化合物，其中R1为H，C1-C6烷基，可以被C3-C6环烷基，氟代C1-C6烷基，C3-C6环烷基，氟代C3-C6环烷基，C3-C6烯基，氟代C3-C6烯基，甲酰基，乙酰基或丙酰基取代；A为苯撑基，吡啶撑基，嘧啶撑基，吡嗪撑基，吡啶并噻吩基或噻吩撑基，可以被卤素，甲基，甲氧基和CF3等一种或多种取代基所取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基，5-或6-成员杂芳基基团中选择的环状基团，该环状基团包括1、2或3个从N、O和S中选择的杂原子和与饱和或不饱和的5-或6-成员碳环或杂环环状并联的苯环，其中杂环包括1、2或3个从N、O和S中选择的杂原子和/或1、2或3个杂原子含量的基团，每个基团独立地选择自NR8，其中R8为H，C1-C4烷基，氟代C1-C4烷基，C1-C4烷基羰基或氟代C1-C4烷基羰基，其中环状基团Ar可以携带1、2或3个取代基Ra；其中变量Ra在权利要求和说明中具有给定的意义；以及其生理耐受酸盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易于用多巴胺D3受体配体治疗的医学疾病的制药组合物。
• Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor
  申请人：Drescher Karla

  公开号：US20110144146A1

  公开（公告）日：2011-06-16

  The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, 0 and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; X is a covalent bond or N—R 2 , CHR 2 , CHR 2 CH 2 , N or C—R 2 ; Y is N—R 2a , CHR 2a , CHR 2a CH 2 or CHR 2a CH 2 CH 2 ; is a single bond or a double bond; E is CH 2 or NR 3 ; R 1 is H, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -alkenyl, R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2 or 3; R 3 is H or C 1 C 4 -alkyl; R 4 and R 5 independently of each other are H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R 6 and R 7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof.

  本发明涉及一种式子I的氨甲基取代的双环芳香化合物，其中Ar是从苯基、包含1、2或3个杂原子的5-或6元素C-键杂环基团（杂原子独立地选自O、S和N），以及与饱和或不饱和的5-或6元素碳环或杂环环融合的苯环，其中杂环环成员选自N、O和S和/或1、2或3个杂原子含量的基团，每个基团独立地选自NR8，其中R8是H、C1-C4-烷基、氟代C1-C4-烷基、C1-C4-烷基羰基或氟代C1-C4-烷基羰基，环状基团Ar可以携带1、2或3个取代基Ra，其中变量Ra的含义在权利要求和说明书中给出；X是共价键或N-R2、CHR2、CHR2CH2、N或C-R2；Y是N-R2a、CHR2a、CHR2aCH2或CHR2aCH2CH2；是单键或双键；E是CH2或NR3；R1是H、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C1-C3-烷基羰基；R1a是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-烯基，R2和R2a各自独立地为H、CH3、CH2F、CHF2或CF3，或者R1a和R2或R1a和R2a一起为(CH2)n，其中n为1、2或3；R3是H或C1-C4-烷基；R4和R5独立地为H、C1-C4-烷基、氟代C1-C4-烷基或C1-C4-烷氧基，或者可以与N一起形成4、5或6元素的饱和或不饱和环；R6和R7独立地为H或卤素；以及其生理耐受的酸加成盐。